Dutch biotech developing vaccine-based cancer immunotherapy targeting tumour blood vessels.
| Date | Round | Amount |
|---|---|---|
| Jun 2022 | Seed Amsterdam cancer-vaccine biotech CimCure, a spin-off from Amsterdam UMC, raised over 5M euros in a seed round to develop its iBoost immunotherapy. | $5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.